Compare LCTX & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | SMTI |
|---|---|---|
| Founded | 1990 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.7M | 313.5M |
| IPO Year | 1996 | 2008 |
| Metric | LCTX | SMTI |
|---|---|---|
| Price | $1.12 | $3,453.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.25 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 891.7K | 455.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,556,000.00 | ★ $15,586,976.00 |
| Revenue This Year | $109.40 | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 53.24 | 32.47 |
| 52 Week Low | $1.00 | $16.05 |
| 52 Week High | $2.09 | $35.70 |
| Indicator | LCTX | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 79.05 |
| Support Level | $1.00 | $33.99 |
| Resistance Level | $1.18 | N/A |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 46.43 | 82.93 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.